Multiplex quantitative assays indicate a need for reevaluating reported small-molecule TrkB agonists
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Quantitative assays suggest that several reported agonists of the receptor TrkB do not indeed activate TrkB signaling.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several proposed low molecular weight TrkB agonists have raised reproducibility and target specificity concerns, and central exposure remains difficult to optimize across scaffolds [131,132].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [132]
In the citing paper
“Many scaffolds suffer rapid clearance, metabolic instability, and uneven brain exposure [62,131,132].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [132]
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“BDNF induced a robust signal in the PathHunter assay with an S/B ratio of 4 to 6 and a Z′-factor, a screening window coefficient that assesses assay quality (44), equal to 0.”
MethodTrk Receptors: Roles in Neuronal Signal Transduction
Huang, E. J., & Reichardt, L. F. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161629 · Cited by 2,537 · cited 1×
“Homodimers of BDNF, NT3, or NT4 induce TrkB dimerization and kinase activation through a series of autophosphorylation events at Tyr(515), Tyr, and Tyr(816) (64).”
BackgroundStress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795
New insights into BDNF function in depression and anxiety
Martinowich, K., Manji, H., & Lu, B. (2007) · Nature Neuroscience · doi:10.1038/nn1971 · Cited by 1,221 · cited 1×
“BDNF infusion into select brain areas of mice or rats shows antidepressant (7–9) and anxiolytic effects (10, 11) by inducing synaptic plasticity (12, 13).”
BackgroundTrkB signalling pathways in LTP and learning
Minichiello, L. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2738 · Cited by 1,055 · cited 1×
“BDNF release and TrkB activation lead to enhanced neurogenesis of different neurochemical cell types, synaptogenesis, and synaptic plasticity (1, 2), all of which affect memory (3) and cognitive enhancements (Fig.”
BackgroundBDNF and synaptic plasticity, cognitive function, and dysfunction
Lu, B., Nagappan, G., & Lu, Y. (2014) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-45106-5_9 · Cited by 1,043
The antidepressant fluoxetine restores plasticity in the adult visual cortex
Vetencourt, J. F. M., Sale, A., Viegi, A., Baroncelli, L., De Pasquale, R., F. O'Leary, O., Castrén, E., & Maffei, L. (2008) · Science · doi:10.1126/science.1150516 · Cited by 890
Castrén, E., & Rantamäki, T. (2010) · Developmental Neurobiology · doi:10.1002/dneu.20758 · Cited by 864
Antidepressant-like effect of brain-derived neurotrophic factor (BDNF)
Siuciak, J. A., Lewis, D. R., Wiegand, S. J., & Lindsay, R. M. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00169-4 · Cited by 841
The promise and peril of chemical probes
Arrowsmith, C. H., Audia, J. E., Austin, C., Baell, J., Bennett, J., Blagg, J., Bountra, C., Brennan, P. E., Brown, P. J., Bunnage, M. E., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1867 · Cited by 839
Cited by
BDNF signaling in context: From synaptic regulation to psychiatric disorders
Wang, C. S., Kavalali, E. T., & Monteggia, L. M. (2022) · Cell · doi:10.1016/j.cell.2021.12.003 · Cited by 607
Targeting synapse function and loss for treatment of neurodegenerative diseases
Dejanovic, B., Sheng, M., & Hanson, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00823-1 · Cited by 194
“However, subsequent studies have raised doubts about these purported small-molecule modulators and whether they bind or activate TrkB 114,115 .”
TrkB/BDNF signaling pathway and its small molecular agonists in CNS injury
Wang, Y., Liang, J., Xu, B., Yang, J., Wu, Z., & Cheng, L. (2024) · Life Sciences · doi:10.1016/j.lfs.2023.122282 · Cited by 152
BDNF signaling during the lifetime of dendritic spines
Zagrebelsky, M., Tacke, C., & Korte, M. (2020) · Cell and Tissue Research · doi:10.1007/s00441-020-03226-5 · Cited by 147
Targeting BDNF/TrkB pathways for preventing or suppressing epilepsy
Lin, T. W., Harward, S. C., Huang, Y. Z., & McNamara, J. O. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107734 · Cited by 117
Numakawa, T., & Kajihara, R. (2025) · Molecules · doi:10.3390/molecules30040848 · Cited by 126
“Their analysis revealed that, unlike BDNF and other neurotrophic factors that activate TrkB, these compounds, including 7,8-DHF and LM22A-4, failed to stimulate critical components of TrkB signaling [134].”
Emili, M., Guidi, S., Uguagliati, B., Giacomini, A., Bartesaghi, R., & Stagni, F. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1810625 · Cited by 85
“A recent study in cell assays failed to confirm that 7,8-DHF activates the TrkB receptor (Boltaev et al. 2017).”
BackgroundTrkB Truncated Isoform Receptors as Transducers and Determinants of BDNF Functions
Tessarollo, L., & Yanpallewar, S. U. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.847572 · Cited by 89
Shi, X., Zhou, X., Chen, G., Luo, W., Zhou, C., He, T.-J., Naik, M. T., Jiang, Q., Marshall, J. J., & Cao, C. (2024) · Science Signaling · doi:10.1126/scisignal.adn4556 · Cited by 61
“Promising small-molecule TrkB agonists have been developed that exert beneficial effects in animal models of depression ( 59 ), although their effects may not be mediated through TrkB activation ( 60 ).”
BackgroundMyelin plasticity in the ventral tegmental area is required for opioid reward
Yalçın, B., Pomrenze, M. B., Malacon, K. E., Drexler, R., Rogers, A. E., Shamardani, K., Chau, I. J., Taylor, K. R., Ni, L., Contreras-Esquivel, D., et al. (2024) · Nature · doi:10.1038/s41586-024-07525-7 · Cited by 66
Levinstein, M. R., Budinich, R. C., Bonaventura, J., Schatzberg, A. F., Zarate, C. A., & Michaelides, M. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240378 · Cited by 61
Szobota, S., Mathur, P. D., Siegel, S., Black, K., Saragovi, H. U., & Foster, A. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224022 · Cited by 60
“The lack of effect of the small molecule TrkB agonists tested conflicts with the original reports of their activity [23, 24, 44] but are in line with more recent papers that have also failed to confirm a direct interaction with TrkB [34, 45, 46].”
ResultTherapeutic potential of a TrkB agonistic antibody for Alzheimer's disease
Wang, S., Yao, H., Xu, Y., Hao, R., Zhang, W., Liu, H., Huang, Y., Guo, W., & Lu, B. (2020) · Theranostics · doi:10.7150/thno.44165 · Cited by 53
“Unfortunately, more rigorous studies recently demonstrated that these molecules neither bind nor activate TrkB [67,68].”
BackgroundResultNeurotrophin-targeted therapeutics: A gateway to cognition and more?
Nordvall, G., Forsell, P., & Sandin, J. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.07.003 · Cited by 48
Neurotrophin signalling in the human nervous system
Ateaque, S., Merkouris, S., & Barde, Y. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1225373 · Cited by 49
The role of neurotrophic factors in novel, rapid psychiatric treatments
Kim, J., He, M. J., Widmann, A. K., & Lee, F. S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01717-x · Cited by 51
“This screen and subsequent testing of the positive hits did not identify any reliable TrkB positive allosteric modulators [199].”
BackgroundTrkB transmembrane domain: bridging structural understanding with therapeutic strategy
Enkavi, G., Girych, M., Moliner, R., Vattulainen, I., & Castrén, E. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.02.001 · Cited by 44
Merkouris, S., Barde, Y., Binley, K. E., Allen, N. D., Stepanov, A. V., Wu, N. C., Grande, G., Lin, C.-W., Li, M., Nan, X., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1806660115 · Cited by 49
“Although a number of studies have reported the discovery of small-molecule mimetics of BDNF that act as TrkB agonists, two recent independent studies have cast doubt on the usefulness of such reagents (17, 21).”
BackgroundRegulation of actions and habits by ventral hippocampal trkB and adolescent corticosteroid exposure
Barfield, E. T., Gerber, K. J., Zimmermann, K. S., Ressler, K. J., Parsons, R. G., & Gourley, S. L. (2017) · PLoS Biology · doi:10.1371/journal.pbio.2003000 · Cited by 46
“Finally, while we find a robust p-ERK42/44 response to repeated 7,8-DHF injections, the ability of acute application to stimulate trkB, ERK42/44, and other factors has been questioned [52].”
BackgroundModulating Neurotrophin Receptor Signaling as a Therapeutic Strategy for Huntington’s Disease
Simmons, D. A. (2017) · Journal of Huntington s Disease · doi:10.3233/jhd-170275 · Cited by 43
Pankiewicz, P., Szybiński, M., Kisielewska, K., Gołębiowski, F., Krzemiński, P., Rutkowska-Włodarczyk, I., Moszczyński-Pętkowski, R., Gurba-Bryśkiewicz, L., Delis, M., Mulewski, K., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14080704 · Cited by 42
“However, the use of 7,8-DHF as a research tool to study TrkB agonism was questioned by other groups who were not able to confirm TrkB activation [25,26].”
BackgroundInfluentialTrkB agonistic antibodies superior to BDNF: Utility in treating motoneuron degeneration
Guo, W., Pang, K., Chen, Y., Wang, S., Li, H., Xu, Y., Han, F., Yao, H., Liu, H., Lopes-Rodrigues, V., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104590 · Cited by 44
Sudarshan, K., Boda, A. K., Dogra, S., Bose, I., Yadav, P. N., & Aidhen, I. S. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.12.057 · Cited by 43
Therapeutic potential of a TrkB agonistic antibody for ischemic brain injury
Han, F., Guan, X.-M., Guo, W., & Lu, B. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.04.009 · Cited by 40
Ron, D., & Berger, A. L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4882-z · Cited by 40
“LM22A-4 has not been used in humans yet, and of note is a recent study which did not detect LM22A-4-dependent activation of TrkB receptor in cell culture models (Boltaev et al. 2017).”
Nguyen, H. T. H., Wood, R. J., Prawdiuk, A. R., Furness, S. G. B., Xiao, J., Murray, S. S., & Fletcher, J. L. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00205 · Cited by 38
“…in Molecular Neuroscience | www.frontiersin.org 8 August 2019 | Volume 12 | Article 205 pharmacokinetic properties of BDNF have led to focused development of BDNF mimetics and small molecule TrkB agonists, including TDP6 and LM22A-4 among others (Longo and Massa, 2013; Boltaev et al., 2017).”
BackgroundResultInfluentialNeuroregeneration in Parkinson’s Disease: From Proteins to Small Molecules
Sidorova, Y. A., Volcho, K. P., & Salakhutdinov, N. F. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180905094123 · Cited by 40
Nie, S., Ma, K., Sun, M., Lee, M., Yang, T., Chen, G., Zhang, Z., Zhang, Z., & Cao, X. (2019) · Parkinson s Disease · doi:10.1155/2019/9193534 · Cited by 41
“Several pieces of research published recently found that 7,8-DHF and various other reported smallmolecule TrkB agonists might not actually be direct agonists of the TrkB and might be mediating their observed effects by other mechanisms [29, 30].”
BackgroundPathogenic Feed-Forward Mechanisms in Alzheimer’s and Parkinson’s Disease Converge on GSK-3
Albeely, A. M., Ryan, S. D., & Perreault, M. L. (2018) · Brain Plasticity · doi:10.3233/bpl-180078 · Cited by 34
Seppa, K., Jagomäe, T., Kukker, K. G., Reimets, R., Pastak, M., Vasar, E., Terasmaa, A., & Plaas, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-81768-6 · Cited by 37
Gonzalez, S., McHugh, T. L. M., Yang, T., Syriani, W., Massa, S. M., Longo, F. M., & Simmons, D. A. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105563 · Cited by 30
Growth factors and their peptide mimetics for treatment of traumatic brain injury
Atkinson, E. A., & Dickman, R. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117368 · Cited by 31
“…small molecule mimetics, a recent publication by Boltaev et al. suggests that these compounds may not in fact lead to phosphorylation of TrkB. 226 Though the authors acknowledged that in vivo activity is of primary importance for the development of therapeutics, they highlighted that these…”
InfluentialZagrebelsky, M., & Körte, M. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.374138 · Cited by 30
“…study applying a series of reliable quantitative methods for direct measurement of TrkB phosphorylation and activation of downstream kinases was unable to reproduce the BDNF-induced robust and dose-dependent receptor activation using several of the TrkB agonist compounds (Boltaev et al., 2017).”
BackgroundZhu, C., Rodda, A. E., Truong, V. X., Shi, Y., Zhou, K., Haynes, J. M., Wang, B. H., Cook, W. D., & Forsythe, J. S. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b00084 · Cited by 28
Targeting brain‐derived neurotrophic factor in the treatment of neurodegenerative diseases: A review
Wang, D., Lang, Z., Wei, S., Wang, W., & Zhang, H. (2024) · Neuroprotection/Neuroprotection (Chichester, England. Print) · doi:10.1002/nep3.43 · Cited by 31
“138 However, in a study utilizing a complementary quantitative assay to directly measure TrkB phosphorylation, 7,8 ‐ DHF and LM22A ‐ 4 failed to reproduce the robust and dose ‐ dependent TrkB receptor activation induced by BDNF. 138,139 The authors propose that the previously reported mechanism of…”
InfluentialDietz, R. M., Orfila, J. E., Rodgers, K. M., Patsos, O. P., Deng, G., Chalmers, N., Quillinan, N., Traystman, R. J., & Herson, P. S. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18766421 · Cited by 22
Foster, A. C., Szobota, S., Piu, F., Jacques, B. E., Moore, D. R., Sanchez, V. A., & Anderson, J. J. (2022) · The Journal of the Acoustical Society of America · doi:10.1121/10.0011510 · Cited by 23
Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in Medulloblastoma
Thomaz, A., Pinheiro, K. D. V., Souza, B. K., Gregianin, L. J., Brunetto, A. L., Brunetto, A. T., de Farias, C. B., Jaeger, M. D. C., Ramaswamy, V., Nör, C., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00698 · Cited by 22
Targeting TrkB–PSD-95 coupling to mitigate neurological disorders
Yang, X., Huang, Y. A., & Marshall, J. J. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-02000 · Cited by 21
“…many TrkB agonists, including 7,8-DHF and LM22-A4, are reported to lack TrkB selectivity or do not activate TrkB signaling directly (Boltaev et al., 2017; Pankiewicz et al., 2021), suggesting these compounds act through mechanisms independent of direct TrkB activation (Boltaev et al., 2017).”
BackgroundBDNF Outperforms TrkB Agonist 7,8,3′-THF in Preserving the Auditory Nerve in Deafened Guinea Pigs
Vink, H. A., van Dorp, W. C., Thomeer, H. G. X. M., Versnel, H., & Ramekers, D. (2020) · Brain Sciences · doi:10.3390/brainsci10110787 · Cited by 20
“[37] measured TrkB and AKT phosphorylation of DHF, and found that DHF did not result in phosphorylation of either.”
BackgroundAdams, I. T., Yang, T., Longo, F. M., & Katz, D. M. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.044685 · Cited by 20
“, 2019), although some in vitro assays have not shown activity (Todd et al., 2014; Boltaev et al., 2017).”
BackgroundMonk, R., Lee, K. C., Jones, K. S., & Connor, B. J. (2021) · Stem Cells · doi:10.1002/stem.3420 · Cited by 21
“should investigate the downstream consequences of impaired TrkB receptor-mediated BDNF signaling in our HD model, although reliable Trk activation assays are currently lacking.(77)”
MethodNatural Psychoplastogens As Antidepressant Agents
Benko, J., & Vranková, S. (2020) · Molecules · doi:10.3390/molecules25051172 · Cited by 19
“Although 7,8-DHF has been able to promote TrkB activation in vivo, it has failed to do so in vitro [94].”
BackgroundRusso, L., Giacomelli, C., Fortino, M., Marzo, T., Ferri, G., Calvello, M., Viegi, A., Magrì, A. L., Pratesi, A., Pietropaolo, A., et al. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00463 · Cited by 18
C3-Symmetric Ligands in Drug Design: When the Target Controls the Aesthetics of the Drug
Antonijevic, M., Rochais, C., & Dallemagne, P. (2023) · Molecules · doi:10.3390/molecules28020679 · Cited by 17
“Even though LM22A-4 was developed as the BDNF mimetic, some findings are actually showing that this molecule is an indirect activator of the TrkB receptor rather than the direct one [33,34].”
BackgroundJaved, S., Chang, Y.-T., Cho, Y., Lee, Y., Chang, H., Haque, M., Lin, Y. C., & Huang, W. (2023) · eLife · doi:10.7554/elife.90333 · Cited by 20
“We recognize that while several in vivo studies have demonstrated the potential of LM22A-4 in targeting neurotrophin downstream signalling ( Kron et al., 2014 ; Li et al., 2017 ), an in vitro analysis failed to demonstrate the ability of LM22A-4 to activate TRKB directly ( Boltaev et al., 2017 ).”
BackgroundShariati, A., Kumar, V., Yang, T., Chakraborty, C., Barres, B. A., Longo, F. M., & Liao, Y. J. (2018) · Current Eye Research · doi:10.1080/02713683.2018.1508726 · Cited by 15
Positive Allosteric Modulators of Trk Receptors for the Treatment of Alzheimer’s Disease
Forsell, P., Parrado Fernández, C., Nilsson, B., Sandin, J., Nordvall, G., & Segerdahl, M. (2024) · Pharmaceuticals · doi:10.3390/ph17080997 · Cited by 14
The regulatory role of the BDNF/TrkB pathway in organ and tissue fibrosis.
Hang, P., Ge, F.-Q., Li, P., Liu, J., Zhu, H., & Zhao, J. (2021) · PubMed · doi:10.14670/hh-18-368 · Cited by 20
Small-Molecule Trk Agonists: Where Do We Go from Here?
Thompson, T. S., Sefiani, A., & Burgess, K. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02365 · Cited by 13
Linking Hypothermia and Altered Metabolism with TrkB Activation
Alitalo, O., González-Hernández, G., Rosenholm, M., Kohtala, P., Matsui, N., Müller, H. K., Theilmann, W., Klein, A. B., Kärkkäinen, O. K., Rozov, S. V., et al. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00350 · Cited by 11
Beresewicz, M. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105455 · Cited by 14
Medicines discovery for auditory disorders: Challenges for industry
Cousins, R. P. C. (2019) · The Journal of the Acoustical Society of America · doi:10.1121/1.5132706 · Cited by 12
de Deus, J. L., Amorim, M. R., Ribeiro, A. B., Filho, P. C. G. D. B., Ceballos, C. C., Branco, L. G. S., Cunha, A. O. S., & Leão, R. M. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00881-8 · Cited by 16
Tacke, C., DiStefano, P. S., Lindsay, R. M., Metzdorf, K., Zagrebelsky, M., & Körte, M. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.945348 · Cited by 12
Antonijevic, M., Charou, D., Ramos, I., Valcárcel, M., Gravanis, A., Villacé, P., Callizot, N., Since, M., Dallemagne, P., Charalampopoulos, I., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115111 · Cited by 13
Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging
Schirrmacher, R., Bailey, J. J., Mossine, A. V., Scott, P. J. H., Kaiser, L., Bartenstein, P., Lindner, S., Kaplan, D. R., Kostikov, A. P., Fricker, G., et al. (2019) · Pharmaceuticals · doi:10.3390/ph12010007 · Cited by 12
“more recently unambiguously demonstrated the lack of direct interaction or TrkB-driven effect of such compounds [34].”
BackgroundDevelopment of Pleiotropic TrkB and 5-HT4 Receptor Ligands as Neuroprotective Agents
Antonijevic, M., Charou, D., Davis, A., Curel, T., Valcárcel, M., Ramos, I., Villacé, P., Claeysen, S., Dallemagne, P., Gravanis, A., et al. (2024) · Molecules · doi:10.3390/molecules29020515 · Cited by 8
“Another issue concerning this molecule is the controversy about its properties in being a direct activator of the TrkB However, even if this activation of the TrkB receptor via LM22A-4 [17,21–23] is indirect, it cannot be disregarded. receptor [19,20].”
BackgroundEnhancing Anti-Tumoral Potential of CD-NHF by Modulating PI3K/Akt Axis in U87 Ex Vivo Glioma Model
Luţa, G., Butura, M., Tiron, A., & Tiron, C. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083873 · Cited by 6
Zaitoun, I. S., Song, Y., Suscha, A., Ragaby, M. E., Sorenson, C. M., & Sheibani, N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0260793 · Cited by 6
Neurotrophic Control of Puberty: From Molecular Signaling to Disorders of Pubertal Timing
Paparella, R., Iafrate, N., Lucibello, R., Bei, A., Bernabei, I., Fiorentini, C., Marchetti, L., Pastore, F., Maglione, V., Niceta, M., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb48010003 · Cited by 6
“However, recent studies have questioned its selectivity, in vivo TrkB activation, and pharmacokinetic suitability, noting poor brain exposure and significant off-target effects, which limit its translational potential for hypothalamic or ovarian targeting [98–100].”
Chanana, V., Zafer, D., Kintner, D. B., Chandrashekhar, J. H., Eickhoff, J. C., Ferrazzano, P. A., Levine, J. E., & Cengiz, P. (2024) · Biology of Sex Differences · doi:10.1186/s13293-024-00596-1 · Cited by 5
“There are studies suggesting that 7,8-DHF may be metabolized to form bioactive products that could result in increases of ERα mRNA expression [43, 44].”
BackgroundResultToward Imaging Tropomyosin Receptor Kinase (Trk) with Positron Emission Tomography
Schirrmacher, R., Bernard‐Gauthier, V., Jaworski, C., Wängler, C., Wängler, B., & Bailey, J. J. (2020) · Springer eBooks · doi:10.1007/978-3-030-53176-8_31 · Cited by 4
Neurotrophin peptidomimetics for the treatment of neurodegenerative diseases
Madhubala, D., Mahato, R., Khan, M. R., Bala, A., & Mukherjee, A. K. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104156 · Cited by 8
High throughput assay for compounds that boost BDNF expression in neurons
Liao, G., Xu, H., Shumate, J., Scampavia, L. D., Spicer, T., & Xu, B. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.02.005 · Cited by 4
7,8-Dihydroxyflavone is a direct inhibitor of human and murine pyridoxal phosphatase
Brenner, M., Zink, C., Witzinger, L., Keller, A., Hadamek, K., Bothe, S., Neuenschwander, M., Villmann, C., von Kries, J. P., Schindelin, H., et al. (2024) · eLife · doi:10.7554/elife.93094 · Cited by 4
“…assays to measure TrkB dimerization and activation, TrkB downstream signaling pathways, TrkB-dependent gene expression and cytoprotection, 7,8-DHF and other reported small-molecule TrkB agonists failed to activate TrkB in cells ( Boltaev et al., 2017 ; Pankiewicz et al., 2021 ; Todd et al., 2014 ).”
BackgroundBoltaev, U., Park, H. W., Brown, K. R., Delgado, M., Wu, J., Diaz-Pacheco, B. N., Botero-Pinzon, M., He, K., Ahern, E., Goldshmid, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.04.583022 · Cited by 4
Self-citationMeCP2 prevents against sustained ketamine-induced synaptic depression at inhibitory synapses
Piazza, M. K., Weit, A. R., Kavalali, E. T., Neul, J. L., & Monteggia, L. M. (2025) · iScience · doi:10.1016/j.isci.2025.112485 · Cited by 3
“First, some studies suggest that LM22A-4 does not activate downstream pathways or phosphorylation of the TrkB receptor in the same way as BDNF. 23,76 However, there is contrary evidence that supports selective TrkB ag-onism and activation of critical downstream pathways such as ERK and PI3K/Akt.”
Disruption of BDNF signalling in neuropathologies
Paulo-Ramos, A., Rhymes, E. R., Villarroel‐Campos, D., & Sleigh, J. N. (2026) · Biochemical Society Transactions · doi:10.1042/bst20253079 · Cited by 6
“Initial reports suggested direct TrkB binding and activation, but other studies have questioned whether 7,8-DHF achieves sufficient brain concentrations to directly activate TrkB, leaving the mechanism of action of TrkB agonists unresolved [153,154].”
A fluorescent electrophile for CLIPS: self indicating TrkB binders
Thompson, T., Pewklang, T., Piyanuch, P., Wanichacheva, N., Kamkaew, A., & Burgess, K. (2023) · Organic & Biomolecular Chemistry · doi:10.1039/d3ob01654d · Cited by 3
Selective Modulation of Trk Receptors by Cyclo-Organopeptides
Joy, S., Mi, T., Lyu, R.-L., Pewklang, T., Thompson, T., Sefiani, A., Kamkaew, A., & Burgess, K. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00833 · Cited by 2
Meng, W., Meng, X., Han, C., Li, Y., Qian, X., & Zhang, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-11594-7 · Cited by 3
“Because of the poor pharmacokinetics of BDNF, many recent studies have focused on identifying small molecule mimetics; however, some have indicated that these mimetics may not induce TrkB phosphorylation, suggesting that BDNF remains the most promising option 33,38 .”
Antonijevic, M., Santos, J. S. O., Dallemagne, P., & Rochais, C. (2024) · Molecular Informatics · doi:10.1002/minf.202400043 · Cited by 1
Zhou, Y., Feng, Y., Li, M., Xi, Y., Zhao, Y., & Chen, X. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110697 · Cited by 1
BDNF-TrkB Signaling in Lifelong Central Nervous System Myelination and Myelin Repair
Nicholson, M., Yoo, S., Craig, G. A., Murray, S. S., & Fletcher, J. L. (2021) · Springer eBooks · doi:10.1007/978-3-030-71519-9_219-1 · Cited by 2
Klettke, E. E., Holmes, M. D., Meyer, T. D., & Jones, G. H. (2023) · Personalized Medicine in Psychiatry · doi:10.1016/j.pmip.2023.100112 · Cited by 1
Selective, Intrinsically Fluorescent Trk Modulating Probes
Pewklang, T., Thompson, T., Sefiani, A., Geoffroy, C. G., Kamkaew, A., & Burgess, K. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00290 · Cited by 2
BDNF-TrkB Signaling in Lifelong Central Nervous System Myelination and Myelin Repair
Nicholson, M., Yoo, S., Craig, G. A., Murray, S. S., & Fletcher, J. L. (2022) · Springer eBooks · doi:10.1007/978-3-031-15080-7_219 · Cited by 1
Javed, S., Chang, Y.-T., Cho, Y., Lee, Y., Chang, H., Haque, M., Lin, Y. C., & Huang, W. (2023) · eLife · doi:10.7554/elife.90333.2 · Cited by 1
Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery
Tanaka, M. (2026) · Biomedicines · doi:10.3390/biomedicines14061265
de Deus, J. L., Amorim, M. R., Ribeiro, A. B., Filho, P. C. G. D. B., Ceballos, C. C., Branco, L. G. S., Cunha, A. O. S., & Leão, R. M. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/850214
“However, the efficacy of LM22A4 and other small molecule agonists of Trk-B receptors has been recently questioned (Boltaev et al., 2017).”
BackgroundTargets, Tracers and Translation – Novel Radiopharmaceuticals Boost Nuclear Medicine
Reischl, G. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-314-6
Fletcher, J. L., Wood, R. J., Prawdiuk, A. R., O’Rafferty, R., Ehrlich, O., Gonsalvez, D. G., & Murray, S. S. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.19.440405
“Further, DHF, like LM22A-4 and 6 other TrkB 191 agonists, have come under scrutiny for their inability to transduce TrkB signalling in a BDNF-like manner 192 [34].”
BackgroundPhysiological basis underlying antidepressant-induced activation of TrkB receptorsPreprint
Alitalo, O., Kohtala, S., Rosenholm, M., Kohtala, P., Saarreharju, R., Matsui, N., González-Hernández, G., Müller, H. K., Theilmann, W., Sarparanta, M. P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.30.458151
Javed, S., Chang, Y.-T., Cho, Y., Lee, Y., Chang, H., Haque, M., Lin, Y. C., & Huang, W. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.30.551185
7,8-Dihydroxyflavone is a direct inhibitor of pyridoxal phosphatasePreprint
Zink, C., Witzinger, L., Keller, A., Hadamek, K., Bothe, S., Neuenschwander, M., Villmann, C., von Kries, J. P., Schindelin, H., Jeanclos, E. M., et al. (2024) · eLife · doi:10.7554/elife.93094.1
7,8-Dihydroxyflavone is a direct inhibitor of pyridoxal phosphatasePreprint
Brenner, M., Zink, C., Witzinger, L., Keller, A., Hadamek, K., Bothe, S., Neuenschwander, M., Villmann, C., von Kries, J. P., Schindelin, H., et al. (2023) · eLife · doi:10.1101/2023.10.04.560852
“However, a direct TrkB agonistic activity of 7,8-DHF has 80 been called into question (32-36).”
BackgroundKetamine’s Multifaceted Neuropharmacological and Neurobiological Actions
Kohtala, S., & Annala, I. (2025) · Neuromethods · doi:10.1007/978-1-0716-4603-8_2
Yang, H.-B., Chen, Y., Nhung, N. T., Hung, E.-Y., & Hung, S. (2026) · Neurochemistry International · doi:10.1016/j.neuint.2026.106235
A De Novo Peptide That Induces Axonal Growth Through TrkB Activation
Maini, R., Tamada, K., Fukuda, K., Takumi, T., & Suga, H. (2026) · ChemBioChem · doi:10.1002/cbic.70517
Patil, S. P., Kuehn, B. R., Schlosser, R., & Samohod, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.10.750759
“In this context, MD simulations revealed highly unstable binding of 7,8-DHF in both the conserved (P-1) and specificity (P-2) pockets of Trk-B, further supporting its observed lack of activity in our reporter assays and prior reports questioning its direct Trk-B agonism [20,21,38].”
Yang, T., Tran, K. C., Leng, A., Langness, V. F., Massa, S. M., & Longo, F. M. (2026) · Cells · doi:10.3390/cells15191822
“Two studies employing cell lines in vitro failed to detect activation of TrkB [122,123], whereas another study suggested that its ability to activate TrkB resulted from transactivation [124].”
Metadata
- Authors
- Boltaev, U., Meyer, Y., Tolibzoda, F., Jacques, T., Gassaway, M., Xu, Q., Wagner, F., Zhang, Y.-L., Palmer, M., Holson, E., & Sames, D.
- Affiliations
- Columbia University (US)
- Broad Institute (US)
- Department of Chemistry, Columbia University, New York, NY 10027, USA.
- Corresponding author
- Boltaev, Umed
- Meyer, Yves
- ORCID
- Venue
- Science Signaling
- Published
- 2017-08-22
- Volume
- 10
- Issue
- 493
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W2745540351
- Cited by
- 94
- References
- 66
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 15 · 2023: 17 · 2022: 7 · 2021: 11 · 2020: 8 · 2019: 11 · 2018: 8 · 2017: 2
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Signaling (publishedVersion)
- PubMed (publishedVersion)
- Funders
- G Harold and Leila Y. Mathers Foundation (award309491)
- Stanley Medical Research Institute, Broad Institute of MIT, and Harvard University (award309492)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- TrkB receptor, brain-derived neurotrophic factor, receptor activation, downstream signaling, gene expression, Alzheimer's disease, major depressive disorder, neurotrophic factors, drug target validation
- MeSH terms
- Animals, Cells, Cultured, Embryo, Mammalian, Enzyme-Linked Immunosorbent Assay, Humans, Membrane Glycoproteins, Neuroblastoma, Neurons, Phosphorylation, Signal Transduction, Brain-Derived Neurotrophic Factor, Receptor, trkB, Flavanones, Rats, Small Molecule Libraries, High-Throughput Screening Assays
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.